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Results
42 studies met inclusion criteria. Of these, 21 (50%) studies did not provide operationalized criteria, whilst in others, criteria varied considerably, particularly regarding symptom severity, prior treatment duration and antipsychotic dose thresholds. Important for the inability to compare results, only two (5%) studies utilized the same criteria. The consensus group identified minimum and optimal criteria, employing the following principles: 1) current symptoms of a minimum duration and severity determined by a standardized rating scale; 2) ≥moderate functional impairment; 3) prior treatment consisting of ≥2 different antipsychotic trials, each for a minimum duration and dose; 4) adherence systematically assessed and P e e r R e v i e w O n l y meeting minimum criteria; 5) ideally at least one prospective treatment trial; 6) criteria that clearly separated responsive from treatment resistant patients.
Conclusions
There is considerable variation in current approaches to defining treatment resistance in schizophrenia. We present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment and treatment response in schizophrenia, providing a benchmark for research and clinical translation. There has been a considerable amount of research into treatment resistance, and its management, which has formed a key component of treatment guidelines around the world (5-8). However, studies have used a variety of different approaches to defining treatment resistance, such that patients included in one study could be excluded from another, as illustrated in figure 1 (9) .
Consequently, comparing studies may be akin to comparing apples to oranges. This is a major hindrance to the field; making the interpretation of meta-analyses difficult, and potentially contributing to failures to replicate findings. For example, a recent network meta-analysis concluded clozapine was no more efficacious than other second-generation antipsychotics for treatment resistant schizophrenia (10) , in contrast to an earlier meta-analysis by the same group that excluded studies focused only on treatment resistant patients (11) . (12) found olanzapine to be efficacious; whilst Buchanan et al. (13) found no benefit for it. Heterogeneity of study designs and populations, including less restrictive definitions of resistance (see figure 1) , may contribute to these inconsistencies (14) .
This lack of uniformity in the definition of treatment resistance also impacts clinical guidelines that seek to distil the evidence from studies. Not surprisingly, given the variation in criteria used in the studies, treatment guidelines use vague definitions that are open to a wide range of interpretations (see table 1), potentially leading to inconsistent clinical management and treatment delays (15; 16) .
In view of this situation, the Treatment Response and Resistance in Psychosis (TRRIP) working group was formed to establish consensus criteria to standardize the definition of treatment resistance. The aim was to develop criteria to aid study design and facilitate comparison of results from different studies. These recommendations are not intended to restrict research using other criteria. However, by providing a consensus benchmark, it will be possible to specify how studies using other criteria differ from the consensus criteria, and to investigate to what degree this might influence results.
General requirements for treatment resistance
Several factors were considered in developing the criteria. First, there is the need for the criteria to encompass a core definition of treatment resistance that captures the worldwide understanding of the concept. Second, the criteria need to be applicable P e e r R e v i e w O n l y across a range of study designs, extending from longitudinal clinical trials and experimental medicine studies, to cross-sectional mechanistic investigations. Third, the criteria need to identify a group of patients who are clearly distinct from nonresistant patients. Finally, there is the need for the criteria to be practical, so that they can be used in a wide range of settings, but still rigorous.
Three key elements define the concept of treatment resistant schizophrenia. These are: 1) a confirmed diagnosis of schizophrenia based on validated criteria; 2) adequate pharmacological treatment; and 3) persistence of significant symptoms despite this treatment. We recognize that the optimal approach to determining lack of treatment response would be identifying patients at their first psychotic episode and prospectively assessing their response to sequential adequate treatment trials.
However, this is unlikely to be practical for the majority of studies, and would be infeasible for identifying the many patients who develop resistance after years of treatment. In view of this fact, criteria need to also allow for cross-sectional identification of treatment resistance.
However, the risk of false positives is likely to be greater with the cross-sectional identification of treatment resistance than with prospective determination. This is because cross-sectional identification requires the retrospective determination of response and adequacy of treatment, and is dependent on potentially less reliable sources of information, such as case-notes and patient or informant report data.
Whilst recognizing that with any approach there is a risk of false positives, it is important to have criteria that are sufficiently rigorous to capture the construct, yet also practical enough to enable studies to be conducted. In view of this we present P e e r R e v i e w O n l y two sets of criteria: minimum and optimum criteria. The optimum criteria are to be used where possible; particularly in clinical trials and hypothesis testing where the false positive rate should be low. The minimum criteria might be used for initial studies and hypothesis generation where there are practical limitations on study design and some false positives can be accepted.
Methods
An iterative approach was adopted to develop criteria for treatment resistance in schizophrenia. Initially, a systematic review of definitions of treatment resistant schizophrenia used in clinical trials was conducted. A literature search of PubMed, PsycINFO, and Embase from January 1980 to January 2016 was undertaken using the search string: "(randomized or random or randomly) and (resistant or refractory or clozapine) and (schizophrenia)". Titles and abstracts were reviewed to initially determine eligibility. The reference lists of each relevant paper were also searched, as were reference lists of relevant review papers, to further identify potential studies.
Studies were included if they were randomized controlled trials of a pharmacological intervention in adults with treatment resistant schizophrenia. Studies were excluded if they were naturalistic, or purely of biomarkers such as neuroimaging measures, studies of adjuvant treatments or non-pharmacological interventions, studies of childhood onset or late onset schizophrenia.
The data extracted were: the prerequisites for previous antipsychotic treatment (requirements of different antipsychotics, minimum treatment duration, dose); the specified severity of symptoms; and whether there was a stipulation for resistance to and refined during subsequent discussions amongst the whole group to derive the consensus recommendations for both minimum and optimum criteria.
Third, the working group met to consider and revise criteria for which there was a lack of consensus. The revised criteria were circulated to the TRRIP working group members, and presented as part of an open workshop at an international meeting in the field for further discussion, input and refinement. Finally, consensus was reached regarding this publication through review by all authors.
TRRIP meetings
Criteria were discussed at the Schizophrenia International Research Society biennial 
Results

Systematic review
2,808 studies were identified of which 42 met selection criteria and were included in the review (see figure 1 ). Operationalized criteria were reported in 21 (50%) studies.
Only two studies out of 42 used identical criteria to define treatment resistance, and defined an adequate treatment episode as lasting at least 6 weeks; and only 22 (52%) studies specified dosage in terms of chlorpromazine equivalents while the remainder used terms such as "adequate" without providing a dose. 20 (48%) studies rated current symptoms using the Brief Psychiatric Rating Scale (18), while 10 (24%) used the Positive and Negative Syndrome Scale (19). 16 (38%) studies employed a prospective phase of supervised treatment as part of the inclusion process. Two (5%) of the studies described assessment of past adherence, but neither described the methods employed to accomplish this.
Consensus recommendations (Table 2)
The consensus criteria are summarized in table 2 and discussed below. See supplementary information for a further discussion of the basis for these recommendations.
Terminology
It is recommended that the term "treatment resistant schizophrenia (TRS)" be used to describe cases of schizophrenia meeting the criteria outlined below, and that use of this term is restricted to patients meeting these criteria. The consistent use of this for schizophrenia, it may be necessary to add treatment specifiers, such as "dopamine blocking" treatment resistant schizophrenia.
Clinical sub-specifiers
The initial trials demonstrating the superiority of clozapine for treatment resistance were undertaken in patients with a high degree of positive symptoms, and in clinical practice this remains the archetypal treatment resistant patient, driven also by the fact that current effective treatments for schizophrenia remain limited to positive symptoms. However, an increasing amount of research has investigated patient groups, that while termed "treatment resistant", may significantly differ from one another in their symptom profile. As a result there is a need for clarity as to patients' clinical profile. A patient's illness may meet criteria based on overall symptoms, or due to specific sub-domains of positive, negative or cognitive symptoms. It may not be appropriate to compare patient groups where the illness is predominantly resistant to treatment in one domain with those in another domain. In view of this, two recommendations are made. First, that the symptom domains used to define resistance are made explicit; and, second, that the domain is specified using the sub-specifiers: positive, negative or cognitive (the latter contingent on developing reliable criteria). Where the patient group is defined as meeting a given threshold of positive symptoms this is specified as "treatment resistant schizophrenia-positive symptom domain", and similarly "treatment resistant schizophrenia-negative symptom domain", and "treatment resistant schizophrenia-cognitive symptom domain" for the other categories. Where more than one domain is involved, this may 
Symptom thresholds
Rating scales
As can be seen from our summary of clinical guidelines for treatment resistance ( (20) , is used to measure current overall, positive and negative symptom severity.
Absolute thresholds
There are two components to the symptomatic assessment of treatment resistance.
The first is the absolute threshold of current severity. It is conceivable, although in practice unlikely, that a patient never has more than mild symptoms, but has not shown a response to a series of treatments. Whilst the patient's symptoms are treatment resistant, there are clinical and methodological risks associated with including such a patient in studies. Firstly, mild severity on rating scales is at the borderline with uncertain symptoms. Given that, even when carefully applied, interrater reliability for rating scales is 0.85-0.9 (21), the measurement error means that there is the risk of including patients with uncertain symptoms. Secondly, the clinical risk-benefit balance in patients with mild symptoms is very different from that in patients with more severe symptoms, where the severity of the condition provides much stronger support for experimental interventions. In view of this, it is recommended that the minimum threshold for current symptoms should be at least moderate severity, as defined on a standardized rating scale.
By the same token, it is conceivable that a patient could have a rating of moderate severity on just one symptom item and no other ratings. Given measurement error, there is the risk that this patient's illness is sub-threshold. Thus, it is recommended that the threshold of at least moderate severity is attained for more than one symptom in the given domain or, if there is only one symptom, that it should be at least severe. These criteria are minimum thresholds that are designed to ensure that patients are clearly currently unwell to a degree that would warrant intervention.
These severity threshold criteria are intended to apply to each domain. So, for example, a study of resistant positive symptoms would require at least two positive symptoms of moderate or greater severity, or at least one symptom with at least a severe rating, and a study of negative symptoms would require at least two negative symptoms at moderate or greater severity, or at least one symptom with at least a severe rating. A study of both resistant negative and resistant positive symptoms would need to meet these criteria in each domain. Of course, a study may recruit patients who are much more severely unwell. We do not mean to preclude research focusing on patients who are not included in these definitions, but recommend that the criteria used are given relative to these criteria so that their differentiating These will enable the establishment of criteria for treatment resistance in the cognitive domain in the future. It should also be noted that factor analyses of rating scales have identified other domains, which may be of interest in specific studies.
We recommend that where these are used they are specified in the same manner as the domains listed here.
Symptom change
The second component of symptomatic assessment is the determination of response to treatment relative to a baseline. Ideally this should be performed prospectively for two treatment episodes with different antipsychotic drugs. Whilst this will not always be practical, it is recommended that there is at least one prospective evaluation of treatment efficacy. If this is not possible, then this should be clearly specified and a retrospective assessment of response to treatment obtained as a minimum. A change of 20% is the minimum that can be routinely detected clinically (24) . Therefore, a reduction less than 20% will correspond to a clinically insignificant reduction in symptoms. It could be argued that larger reductions may still not be clinically meaningful. However, given that an improvement of ≥20% has been used to identify treatment responders (25) , requiring <20% reduction ensures the treatment resistant group does not overlap with treatment responders. Therefore, it is recommended that at the end of the prospective evaluation the absolute symptom severity rating criteria above are still met, and that symptom reduction should be <20% both for the total rating and specific domain of interest before such a patient be included in a prospective treatment trial of treatment-resistant schizophrenia. In the event that a patient shows an improvement of ≥20% during the prospective observation period, then the patient should be re-evaluated and, if he/she still fulfils absolute criteria for treatment-resistance be observed for another prospective evaluation period. Only patients who during the prospective observation improve by <20% and still fulfill absolute severity thresholds for treatment resistance should be called treatment-resistant and included in prospective studies. In contrast, precise quantitative assessment is unlikely to be feasible for retrospective evaluation (which is exactly why we recommend prospective evaluation of treatment resistance).
Therefore, for past treatment episodes, we recommend that patients should be rated as less than 'minimally improved' on the overall change in the Clinical Global Impression-Schizophrenia Scale (26) . It is recommended that multiple sources of information, including patient and caregiver reports, case notes and staff report, are used to evaluate past response. Nevertheless, as measurement error is likely to be larger in the retrospective evaluation of response to past treatment, in order to be conservative, it is recommended that where there is missing information or doubt, investigators err on the side of caution and exclude subjects or prospectively 
Functional impact
It is of course conceivable that a subject has symptoms at threshold severity, but that these have little functional impact (28; 29). Thus, in addition to symptom severity it is recommended that functional impairment is measured using a recognized, validated measure and that this is reported. Scales that just index functioning, such as the Role Functioning Scale (30) or the Social and Occupational Functioning Scale (SOFAS) (31), are preferred over scales that include symptom assessment as part of the measure as symptom severity can strongly influence ratings. To be consistent with required symptom thresholds, we propose that there is moderate (eg: score <60 on SOFAS) or more severe functional impairment.
Distress caused by symptoms is also an important factor to consider. However, due to lack of insight associated with schizophrenia (32), some patients may not report distress. Furthermore, distress is de facto subjective and difficult to operationalize. In view of these factors, it is recommended that subjective distress should not be a requirement (although recording or measuring it is desirable to capture patientcentered outcomes). (1; 21) . Therefore, it is necessary to establish that symptoms have persisted over a reasonable period of time to be clear that a patient is truly treatment resistant. It is recommended that a minimum of 12 weeks duration of symptoms be used, during which symptoms and functional impairment are of at least moderate severity threshold severity and that the minimum duration be clearly identified.
Characterizing treatment resistance
Degree:
Treatment resistance is mostly treated as a binary variable as a study entry or treatment decision criterion in research and clinical practice. This is often necessary for research purposes and when making clinical decisions. Clinically, however a continuum is apparent (33) . As such, carefully characterizing patients will aide a finer grained assessment of biological mechanisms or treatment effects in well-defined subgroups of patients with treatment resistance. Thus, it is recommended that symptom and functional measures are reported in as much detail as possible. As a minimum, this should include positive and negative symptom ratings using a validated instrument such as the BPRS, PANSS or SAPS and SANS and a measure of functional impairment using a validated measure such as the Role Functioning Scale or SOFAS (17; 19; 20; 31; 34; 35) . These measures should also be used to characterize change after an intervention, as treatment may affect certain symptom domains more than others. This characterization will facilitate research into the 
Temporal development
A further issue is when treatment resistance begins. Studies show that treatment resistance is present from illness onset in some patients, whilst in others the illness shows an initial response to treatment, but subsequently resistance develops (36) (37) (38) (39) (40) . From a theoretical perspective, both the mechanisms underlying resistance and the therapeutic implications may be different in these two situations: for example, clozapine does not show clear superiority over other antipsychotic drugs in nontreatment resistant first episode patients (41; 42) . Whilst the importance of this is not clear, to facilitate research into these issues, it is recommended that it is specified whether patients have been treatment resistant from within the first year of treatment (early-onset treatment resistance), or have developed it during 1 to five years after onset of treatment (medium-term onset treatment resistance), or later than five years after onset of treatment (late-onset treatment resistance). Ideally, the duration of treatment resistance should also be ascertained and reported. Other factors posited to be relevant to the pathophysiology of resistance, such as development of resistance following relapse and misuse of substances, should be recorded where possible (43) . It is important to note that duration of treatment resistance relates to treatment onset and not illness onset, otherwise it could be confounded by duration of untreated psychosis. It could always be argued that a patient may respond if treatment is given for a little longer, which, taken to the extreme, leads to the requirement that a patient would need to take a given treatment for life to be certain they will not respond. However, few non-responders within the first 6 weeks go on to respond at later time points, and clinical trials for licensing, which form a large basis of the evidence base, generally last 4-6 weeks. (44) Clearly there is the need to balance the risk of false positives with practical considerations. Thus it is recommended that each antipsychotic treatment episode should have lasted at least 6 weeks, at a therapeutic dose (see 5.2), to be deemed 'adequate'. Thus, given the minimum number of different antipsychotic treatment episodes (see 5.3), the minimum duration of treatment required is 12 weeks. As outlined below (see 5.5), to rule out "pseudo-resistance" due to inadequate treatment adherence, the optimal definition of treatment resistance would include at least one failed trial with a long-acting injectable antipsychotic (LAI), given for at least 6 weeks after it has achieved steady state (generally at least 4 months from commencing treatment) (45; 46).
Defining Adequate Treatment
Duration:
Dose:
For a treatment episode to be deemed therapeutic, the minimum dose of prescribed oral or injectable antipsychotic should be the target dose (or mid-point of the target dose range) for the acute treatment of schizophrenia given in the manufacturer's summary of product characteristics. If this is not clear or practical, it is recommended that a total daily dose equivalent to 600mg of chlorpromazine per day (determined using established conversion ratios such as those given in recent papers regarding dose conversion (47) (48) (49) ) is used as the minimum. It is recommended to err on the side of a higher minimum dose where there is a range of possibilities. If a trial has to 
Number of past treatment episodes:
Failure of at least two adequate treatment episodes with different antipsychotic drugs, each meeting the above criteria, is required to establish treatment resistance.
In some clinical guidelines it is recommended that these trials include different types of antipsychotic (such as first-and second-generation drugs) (table 1) . However,
given the overlap in side-effects, efficacy and receptor profiles among currently available non-clozapine antipsychotics, the consensus was that the current data do not provide unequivocal support for therapeutic categories of different antipsychotic drugs (11; 50). There was some disagreement about this conclusion amongst the working group members, as olanzapine, risperidone and amisulpride show consistent, though small, advantages in meta-analyses of efficacy (51) . However, consensus was reached that, when considering this from a practical perspective as well, specifying particular drug(s) would limit generalizability, not least because a given drug may not be readily available in some settings (for example, amisulpride in the USA). In view of this, a requirement to use particular categories or drugs (apart from clozapine) is not currently recommended. Of course, particular drugs may be stipulated in a given study where there is a specific reason to focus on patients who
have not responded to a certain drug or group of drugs. In practice, many patients will have tried a large number of different drugs (16) . In view of this, the total number of failed adequate antipsychotic treatment trials, the drugs and their dose and route, should be ascertained and reported where possible. As mentioned above, a trial with It terms of both duration and number of treatment trials, it is necessary to promptly optimize treatment, yet to also minimize the risk of prematurely discarding potentially effective treatments. Arguments can be made for extending treatment trials, given that a proportion of patients appear to show a delayed response (52) , conversely it can also be argued that treatment with a second non-clozapine antipsychotic after initial treatment failure is not warranted, given that response rates seem to be below 20% (36) . The proposed criterion of at least two trials lasting a minimum of 6-weeks aims to strike a balance between these two opposing views.
Clozapine resistant schizophrenia:
For clarity and due to the specific role of clozapine in the treatment of resistant schizophrenia (53-57), failure to respond to clozapine is to be used as a subspecifier of treatment resistant illness, i.e., clozapine-resistant schizophrenia. In addition to using the mid-dose range as a minimum requirement for an adequate trial, and the adherence requirements below (5.5), it is recommended that trough serum levels of clozapine are measured on at least two occasions separated by at least a week at a stable dose of clozapine. This is important not only to establish adherence, but also because of the link between serum levels of clozapine and response (58) (59) (60) (61) (62) .
Clozapine levels ≥350 ng/ml (63) constitute an optimum threshold requirement for establishing non-response to clozapine treatment. It is strongly recommended that levels are used, not least because of the major effect of smoking and gender on clozapine's pharmacokinetics, but where obtaining blood is not possible, a minimum was only at doses of over 400mg a day that clozapine proved superior to other antipsychotics in a met-analysis of head-to-head comparisons (64) . The duration of an adequate trial of clozapine remains to be definitively determined (65) . A number of studies have recommended trial durations of between 4 and 12 months (66-68).
Others, however, have suggested that the time course of response is not significantly different to non-clozapine antipsychotics (69) (70) (71) , and the perception of a delayed response may primarily be due to the time taken to reach a therapeutic level (72) . Due to the lack of clarity as to where to proceed following a failed clozapine trial, and the clinical effort required to establish treatment with clozapine, we recommend clozapine therapy should be tried for a duration of at least 3 months following attainment of therapeutic plasma levels.
Adherence:
Due to difficulties with adhering to dosing schedules, lack of illness insight, side effect burden, cognitive impairment and other factors, non-adherence is a significant problem in the treatment of schizophrenia and is often under-recognized (73) (74) (75) (76) .
Non-adherence may be the single largest source of unrecognized error in studies of treatment resistance (73) . Consequently, it is important to make strenuous efforts to determine adherence and apply criteria to exclude poorly adherent subjects who can represent false positive "pseudo-resistant" cases. Whilst 100% adherence is rare even in clinical trial settings (77; 78) , it is necessary to be close to this figure, otherwise the study will be of non-adherence rather than of treatment resistance. As a minimum, it is recommended that patients have taken ≥80% of prescribed doses at the prescribed dosage level over the required ≥12-week treatment period during which the criteria for treatment resistance have persisted. This adherence level should be determined by as many sources as feasible, including a minimum of two out of: pill counts, dispensing chart review and patient/caregiver report. Sources should be specified, but patient report alone is unlikely to be sufficient (34) . In addition, given that there may still be covert non-adherence, antipsychotic blood levels should be determined in all patients taking oral medication on at least one occasion (and optimally ≥2 occasions each separated by at least two weeks).
Because anticipation of blood could encourage an unrepresentative period of increased adherence beforehand, tests need to be conducted without advance notice of when. Where guidelines (such as the Maudsley Prescribing Guidelines (79)) indicate a minimum plasma level associated with response, this should be used as a minimum criterion. However, where there is a lack of consensus as to what is a therapeutic plasma level, a minimum level will need to be set based on what can be expected in people regularly taking the drug at a therapeutic dose (80).
Nevertheless, unless blood level monitoring is very frequent, covert non-adherence is still possible. Thus, where possible, or as a pragmatic and likely superior alternative to documenting adequate antipsychotic blood levels on at least one occasion, it is recommended that one of the failed treatment episodes involves a LAI; or alternatively, that adherence has been monitored via direct observation or with technological assistance (81). Cross-sectional and mechanistic studies will often require a comparator group of participants who have shown a good response to treatment. For consistency, the same clinical rating scales need to be used to identify this group as are used to identify the treatment resistant group. In addition, the criteria need to ensure that there is a clear distinction between groups. This precondition requires that the criteria make allowance for measurement error, and have clear separation of thresholds; to avoid the inclusion of participants rated in a borderline zone who are potentially eligible for both groups, dependent on the rater or day that they are rated.
Defining adequate treatment responders
As such, it is recommended that as an absolute symptom threshold responders show no more than mild symptom severity across the symptom items in the domain(s) of interest, and have shown this over at least 12 weeks. Where possible it is recommended that response is ascertained prospectively over at least 6 weeks and defined as at least a 20% improvement in symptom scores for the domain of interest as well as meeting the absolute thresholds. Furthermore, there may be circumstances, for example studies in first episode patients, where this threshold may be of insufficient stringency. In these circumstances investigators may choose even more rigorous stability criteria to define adequate treatment response, such as having achieved remission, consisting of no more than mild positive and negative symptoms for ≥6 months (8), or no symptoms at all. In addition to the symptom severity threshold, current functional impairment should not be more than mild (eg >60 on SOFAS) in all circumstances (see table 3 for a summary of criteria).
Discussion
Page 30 of 46 The American Journal of Psychiatry P e e r R e v i e w O n l y Our review of the criteria currently used to define treatment resistance in clinical trials identified significant limitations in published studies. Notably, 50% of studies did not use fully operationalized criteria, rendering it impossible to accurately replicate these studies. Furthermore, there was wide variation in the criteria used, with 95% of studies using different criteria, complicating comparisons across studies. Finally, key aspects of determining treatment resistance were not specified in many studies. For example, assessment of prior antipsychotic adherence was not specified in 95% of studies. These findings indicate a need for criteria that can be used as a benchmark for future studies.
We developed criteria to address this need. Across a wide range of areas, there was a relatively clear consensus in the working group as to how to best define treatment resistant schizophrenia. A summary of the consensus criteria is shown in table 2.
The criteria we suggest show agreement in a number of domains with those used in the majority of previous studies in the literature, in particular the requirements for at least two failed treatment trials each of a minimum of six weeks, and the use of standardized rating scales (supplementary table 1). However, our recommendations differ from approaches used by most studies in the literature to date in several key domains. In particular, our recommendations have clear criteria for ensuring adequate adherence, and for the inclusion of functional impairment. Furthermore, our recommendations include specifiers to characterize the sample, and cover reporting standards to aid comparisons across studies. Finally, we recommend a lower minimum antipsychotic dose than many early studies required, reflecting the recognition in the field that very high doses generally increase the risk of side-effects without additional therapeutic benefit. 
Strengths and Limitations
The recommendations presented here have been developed through an iterative process and in consultation with expert researchers and clinicians from across the world. As such, they extend previous recommendations (e.g. (82; 83) ) to reflect a wide body of opinion, and have been refined to be applicable to a variety of settings.
Nevertheless, a limitation is that they may not reflect practice or opinion in all locations. We have attempted to consult widely to mitigate this issue, and sought to produce criteria that are sufficiently representative as to be useful to the field. Although not all invited experts responded to the online survey, they all participated in discussions and the development of the consensus criteria. Moreover, whilst the survey identified some areas where there were small majorities (see supplementary information), subsequent discussions clarified and refined the criteria to enable agreement and all participants subscribe to the final criteria presented here.
Although in clinical care and in treatment guidelines, antipsychotic treatment combined with psychosocial strategies is advocated for the optimal care of people with schizophrenia, we did not specify a minimum level of "adequate" psychosocial interventions as a prerequisite before treatment resistance could be defined. This decision was not based on an underestimate of the importance of psychosocial treatments, but rather based on the current lack of operationalized criteria for determining adequate psychosocial treatment (84) . We anticipate revising this aspect once initiatives to develop criteria have reported data that will allow for a standardized approach.
An important conceptual issue is that the recommendations are based on clinical criteria only. The clinical end-point may incorporate multiple pathophysiological pathways, which may have different treatment implications. As such, whilst clinical criteria are the current state-of-the-art, we anticipate that ultimately the classification will be revised and informed by the underlying biology and mechanisms as evidence on these emerges (85) (86) (87) . A further potential issue is that there is likely a continuum of treatment response, and that dichotomous categories such as "adequate treatment response" and "treatment resistance" are crude and reductionistic. The endorsement of some (established) rating scales or some "cutoffs" to achieve this, from a list of many other potentially useful options, may be considered as a compromise. Whilst we acknowledge this, clinicians and patients have to make choices about whether to continue with a given treatment, and research studies require patients to be randomized to a given treatment. In this context, the categorisation we propose aims to prioritize specificity over sensitivity and should help facilitate both clinical care and research decisions.
The criteria recommended here reflect a consensus on the balance between practical considerations, the risk of false positives and the potential to translate findings derived from studies into clinical practice. It is acknowledged that alternative cut-offs may be more appropriate in specific studies, but we recommend that these criteria are specified in reference to the benchmarks outlined here, so that it is clear in what way the criteria are different.
Finally, we have codified the concept that treatment resistance may develop at different stages of the illness, or be present from illness onset. Clinically, it is clear that there are some patients who initially experience a good response to antipsychotic treatment and treatment resistance later develops, whilst others have little or no response from illness onset (36) (37) (38) (39) (40) . This is of considerable potential clinical and mechanistic importance. However, despite this wide-spread clinical observation, there is relatively little research evidence on this issue (36) (37) (38) (39) (40) However, practical considerations required a cut-off that would be easy to apply and that reflected widespread clinical and research definitions of the early course of schizophrenia, which include the first five years following illness onset (88; 89) . It is intended that the criteria will stimulate research into whether there are differences between patients who develop treatment resistance early, late or from illness onset, and clarify the reporting of studies. We have developed operationalized criteria to address this issue based on a process of wide consultation and refinement, involving expert researchers and clinicians, scientists from the pharmaceutical industry and other specialists who are active in Current Adherence ≥80% of prescribed doses taken. Adherence should be assessed using ≥ 2 of pill counts, dispensing chart reviews and patient/carer report. Antipsychotic plasma levels monitored on at least one occasion. Specify methods used to establish adherence.
Conclusions and future directions
As for minimum criteria and additionally trough antipsychotic serum levels measured on at least two occasions separated by at least two weeks (without prior notification of patient). 
Symptom Domain
